Annexon’s ANX007 Misses GA Endpoint, But May Have Visual Acuity Path Forward

The ARCHER study did not show improvement in lesion growth, but still showed an improvement in best corrected visual acuity, potentially opening a pathway toward a pivotal trial.

Annexon announced results of the Phase II ARCHER study of ANX007 in geographic atrophy • Source: Shutterstock

Annexon Biosciences is looking to map out a path forward for ANX007 in geographic atrophy (GA) after a Phase II study failed to meet the primary endpoint typically used for US Food and Drug Administration approval, based on an improvement in visual function. But it’s a space where Apellis Pharmaceuticals, Inc.’s Syfovre (pegcetacoplan) has already won approval, and Iveric Bio’s Zimura (avacincaptad pegol) is undergoing FDA review, with a decision anticipated in the coming months.

The biotech company unveiled topline results on 24 May from the Phase II ARCHER study, announcing that the trial did not meet the primary endpoint of change in GA lesion...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Mission Vision: How Roche Hopes To Impact Eye Health Outcomes In APAC

20 May 2025

• By Anju Ghangurde

Roche Pharmaceuticals’ area head, Asia Pacific, outlines how the Swiss group is helping nurture the wider ecosystem and setting itself up for a bigger play in the ophthalmology space by combining scientific expertise with regional insights.

Merck & Co. CMO Barr On Breaking Into Immunology And Ophthalmology

02 May 2025

• By Jessica Merrill

Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.

In Brief: US FDA Rejects Regeneron’s Bid to Extend Eylea HD Dosing

22 Apr 2025

• By Sushmita Panda

Regeneron is disappointed by the knock-back for longer dosing intervals for its high-dose version of Eylea, but its supplemental application for a more commercially important shorter four-week regimen has received a priority review.

Outlook Holds Out Hope For Wet AMD Approval Despite Phase III Topline Miss

28 Nov 2024

• By Alaric DeArment

The company said the NORSE EIGHT trial of ONS-5010 did not meet the primary endpoint of showing noninferiority to ranibizumab, but it still plans to file for US FDA approval.